Microbial natural products: Molecular blueprints for antitumor drugs

Journal of Industrial Microbiology and Biotechnology

Volumn 40, Issue 11, 2013, Pages 1181-1210

  Giddings, Lesley Ann ^a   Newman, David J ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Cancer drugs; Clinical trial; Microbial genome; Microbial natural product

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ANTINEOPLASTIC AGENT; BECATECARIN; BERUBICIN; BLEOMYCIN; BRYOSTATIN 1; CALICHEAMICIN; CARFILZOMIB; DACTINOMYCIN; DOLASTATIN 10; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; ERIBULIN; EVEROLIMUS; GELDANAMYCIN; HALICHONDRIN B; KAHALALIDE F; LESTAURTINIB; MIDOSTAURIN; NATURAL PRODUCT; RAPAMYCIN; RIDAFOROLIMUS; ROMIDEPSIN; SAGOPILONE; SALINOSPORAMIDE A; STAUROSPORINE; TANESPIMYCIN; TRABECTEDIN; UNINDEXED DRUG;

ACTINOMYCETALES; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASPERGILLUS NIDULANS; BILE DUCT TUMOR; BONE CANCER; BRAIN CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHROMOBACTERIUM VIOLACEUM; COMBINATORIAL CHEMISTRY; CONGESTIVE HEART FAILURE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; ENDOPHYTE; GENE CLUSTER; GENETIC MANIPULATION; GENOME; GERM CELL TUMOR; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MICROORGANISM; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROCHLORON; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; SOIL MICROFLORA; SOLID TUMOR; SORANGIUM CELLULOSUM; SQUAMOUS CELL CARCINOMA; STREPTOMYCES; SYSTEMIC MASTOCYTOSIS; THYROID CANCER; UTERINE CERVIX CARCINOMA;

EUKARYOTA; PROKARYOTA;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG DESIGN; GENOMICS; HUMANS;

EID: 84886297369     PISSN: 13675435     EISSN: 14765535     Source Type: Journal    
DOI: 10.1007/s10295-013-1331-1     Document Type: Review

References (244)

1. Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S (1993) PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell 75:1263-1271
2. Abou-Gharbia M, Childers W (2012) Targeting neurodegenerative diseases: drug discovery in a challenging arena. Pure Appl Chem 84:1543-1556
3. Ahn KS, Sethi G, Chao T-H, Neuteboom STC, Chaturvedi MM, Palladino MA, Younes A, Aggarwal BB (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB regulated gene products. Blood 110:2286-2295
4. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, Matelich MC, Scola PM, Spero DM, Yoon SK (1992) Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 114:3162-3164
5. Akiyama Y, Ma Q, Edgar E, Laikhter A, Hecht SM (2008) Identification of strong DNA binding motifs for bleomycin. J Am Chem Soc 130:9650-9651
6. Altmann K-H, Gaugaz FZ, Schiess R (2011) Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives. Mol Divers 15:383-399
7. Animati F, Berettoni M, Bigioni M, Binaschi M, Cipollone A, Irrissuto C, Nardelli F, Olivieri L (2012) Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety. Bioorg Med Chem Lett 22:5013-5017
8. Animati F, Berettoni M, Bigioni M, Binaschi M, Felicetti P, Gontrani L, Incani O, Madami A, Monteagudo E, Olivieri L, Resta S, Rossi C, Cipollone A (2008) Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety. Chem Med Chem 3:266-279
9. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17:2734-2743
10. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266:15882-15889
11. Baker H, Sidorowicz A, Sehgal SN, Vezina C (1978) Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot 31:539-545
12. Bandara WMMS, Seneviratne G, Kulasooriya SA (2006) Interactions among endophytic bacteria and fungi: effects and potentials. J Biosci 31:645-650
13. Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC (2009) Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol 84:484-487
14. Belecki K, Townsend CA (2012) Environmental control of the calicheamicin polyketide synthase leads to detection of a programmed octaketide and a proposal for enediyne biosynthesis. Angew Chem Int Ed 51:11316-11319
15. Bergmann W, Burke DC (1955) Marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. J Org Chem 20:1501-1507
16. Bergmann W, Feeney RJ (1950) Isolation of a new thymine pentoside from sponges. J Am Chem Soc 72:2809-2810
17. Bergmann W, Feeney RJ (1951) Marine products. XXXII. The nucleosides of sponges, I. J Org Chem 16:981-987
18. Birren BW, Clifton SW, Highlander SK, Nelson KE, Petrosino JF, Sodergren E, Strausberg RL, Sutton GG, Weinstock GM, White OR (2010) A catalog of reference genomes from the human microbiome. Science 328:994-999
19. Bitzer J, Gesheva V, Zeeck A (2006) Actinomycins with altered threonine units in the β-peptidolactone. J Nat Prod 69:1153-1157
20. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch JM, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
21. Bomar L, Maltz M, Colston S, Graf J (2011) Directed culturing of microorganisms using metatranscriptomics. mBio 2:e00012-00011
22. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F (2008) Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 113:360-366
23. Bowers AA, Greshock TJ, West N, Estiu G, Schreiber SL, Wiest O, Williams RM, Bradner JE (2009) Synthesis and conformation and activity relationships of the peptide isosteres of FK228 and largazole. J Am Chem Soc 131:2900-2905
24. Brown EJ, Albers MW, Bum Shin T, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758
25. Bulgarelli D, Rott M, Schlaeppi K, Loren Ver, van Themaat E, Ahmadinejad N, Assenza F, Rauf P, Huettel B, Reinhardt R, Schmelzer E, Peplies J, Gloeckner FO, Amann R, Eickhorst T, Schulze-Lefert P (2012) Revealing structure and assembly cues for Arabidopsis root-inhabiting bacterial microbiota. Nature 488:91-95
26. Caboche S, Pupin M, Leclére V, Fontaine A, Jacques P, Kucherov G (2008) NORINE: a database of nonribosomal peptides. Nucleic Acids Res 36:D326-D331
27. Celldex Therapeutics (2012) CDX-011; EMERGE topline data. http://ir.celldextherapeutics.com/events.cfm
28. Chambraud B, Belabes H, Fontaine-Lenoir V, Fellous A, Baulieu EE (2007) The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J 21:2787-2797
29. Chandra S (2012) Endophytic fungi: novel sources of anticancer lead molecules. Appl Microbiol Biotechnol 95:47-59
30. Chang H, Yeh M (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 7:49-60
31. Chen C, Si S, He Q, Xu H, Lu M, Xie Y, Wang Y, Chen R (2008) Isolation and characterization of antibiotic NC0604, a new analogue of bleomycin. J Antibiot 61:747-751
32. Chen C, Song F, Wang Q, Abdel-Mageed WM, Guo H, Fu C, Hou W, Dai H, Liu X, Yang N, Xie F, Yu K, Chen R, Zhang L (2012) A marine-derived Streptomyces sp. MS449 produces high yield of actinomycin X2 and actinomycin D with potent anti-tuberculosis activity. Appl Microbiol Biotechnol 95:919-927
33. Chen Z-H, Wang B-L, Kale AJ, Moore BS, Wang R-W, Qing F-L (2012) Coupling of sterically hindered aldehyde with fluorinated synthons: stereoselective synthesis of fluorinated analogues of salinosporamide A. J Fluorine Chem 136:12-19
34. Cheng-Zhu W, Jang J-H, Ahn J-S, Hong Y-S (2012) New geldanamycin analogs from Streptomyces hygroscopicus. J Microbiol Biotechnol 22:1478-1481
35. Cheng Y-Q (2012) Sequences for FK228 biosynthesis and methods of synthesizing FK228 and FK228 analogs. US Patent US 8,148,102 B2, 03 Apr 2012
36. Cheng Y-Q, Yang M, Matter AM (2007) Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968. Appl Environ Microbiol 73:3460-3469
37. Cho YS, Wu K-D, Moore MAS, Chou T-C, Danishefsky SJ (2005) Second-generation epothilones: discovery of fludelone and its extraordinary antitumor properties. Drugs Future 30:737-745
38. Chou T-C, Zhang X, Zhong Z, Li Y, Feng L, Eng S, Myles DC, Johnson RG Jr, Wu N, Yin YI, Wilson MW, Danishefsky SJ (2008) Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci USA 105:13157-13162
39. Conway KR, Boddy CN (2012) ClusterMine360: a database of microbial PKS/NRPS biosynthesis. Nucleic Acids Res 41:D402-D407
40. Corey EJ, Gin DY, Kania RS (1996) Enantioselective total synthesis of ecteinascidin 743. J Am Chem Soc 118:9202-9203
41. ® (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26:322-337
42. ®. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 291-316
43. Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, de la Calle F, García J, Polanco C, Rodríguez I, Manzanares I (2000) Synthesis of ecteinascidin Et-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2:2545-2548
44. D'Incalci M, Galmarini CM (2010) A review of trabectedin (Et-743): a unique mechanism of action. Mol Cancer Ther 9:2157-2163
45. Danishefsky S (2010) On the potential of natural products in the discovery of pharma leads: a case for reassessment. Nat Prod Rep 27:1114-1116
46. Davidson SK, Allen SW, Lim GE, Anderson CM, Haygood MG (2001) Evidence for the biosynthesis of bryostatins by the bacterial symbiont, Candidatus Endobugula sertula, of the bryozoan Bugula neritina. Appl Environ Microbiol 67:4531-4537
47. Davies S, Panidian R, Bolos J, Castaner R (2009) Carfilzomib. Drugs Future 34:708-716
48. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee ST, Sang Kim Y, Chen Y, Ning Y-M, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB (2011) Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 108:11878-11883
49. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB (2003) Histone deacetylases: characterization of the classical HDAC family. Biochem J 370:737-749
50. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot 23:442-447
51. DeChristopher BA, Loy B, Marsden A, Schrier AJ, Zack JA, Wender PA (2012) Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 4:705-710
52. Di Maro S, Pong R-C, Hsieh J-T, Ahn J-M (2008) Efficient solid -phase synthesis of FK228 analogues as potent antitumoral agents. J Med Chem 51:6639-6641
53. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J Biol Chem 271:7273-7276
54. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981-989
55. Donia MS, Fricke WF, Partensky F, Cox J, Elshahawi SI, White JR, Phillippy AM, Schatz MC, Piel J, Haygood MG, Ravel J, Schmidt EW (2011) Complex microbiome underlying secondary and primary metabolism in the tunicate-Prochloron symbiosis. Proc Natl Acad Sci USA 108:E1423-E1432
56. Edler MC, Fernandez AM, Lassota P, Ireland CM, Barrows LR (2002) Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10. Biochem Pharmacol 63:707-715
57. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM (1999) Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′, β′-epoxyketones. Chem Biol 6:811-822
58. Eng CP, Sehgal SN, Vezina C (1984) Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 37:1231-1237
59. Eustaquio AS, Moore BS (2008) Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew Chem Int Ed 47:3936-3938
60. Eustáquio AS, O'Hagan D, Moore BS (2010) Engineering fluorometabolite production: fluorinase expression in Salinispora tropica yields fluorosalinosporamide. J Nat Prod 73:378-382
61. Evans DA, Carter PH, Carreira EM, Prunet JA, Charette AB, Lautens M (1998) Asymmetric synthesis of bryostatin 2. Angew Chem Int Ed 37:2354-2359
62. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 42:355-357
63. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731
64. Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C (2012) Novel drugs targeting microtubules: the role of epothilones. Curr Pharm Des 18:2793-2803
65. Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C, Fox EM, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer tD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ (2010) Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28:4339-4345
66. Flahive E, Srirangam J (2012) The dolastatins: novel antitumor agents from Dolabella auricularia. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 263-290
67. Furumai R, Matsuyama A, Kobashi N, Lee K, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921
68. Gao J, Hamann MT (2011) Chemistry and biology of kahalalides. Chem Rev 111:3208-3235
69. García-Rocha M, Bonay P, Avila J (1996) The antitumoral compound kahalalide F acts on cell lysosomes. Cancer Lett 99:43-50
70. Gniazdowski M, Denny WA, Nelson SM, Czyz M (2003) Transcription factors as targets for DNA-interacting drugs. Curr Med Chem 10:909-924
71. Goel S, Moran T, Coronado C, Ramirez SV, Chaudhary I, Ghalib MH, Sawami U, Hou Y, Carcereny E, Alcantara J, Dios JLI, De Miguel B, Buges C, Rosell R (2012) Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors. J Clin Oncol Suppl 30:Abst. 3093
72. Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, DeAngelo DJ, Kepten I, Lanza C, Heinemann H, Yin O, Gallagher N, Graubert T (2007) The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. Blood 110:1035A
73. Greshock TJ, Johns DM, Noguchi Y, Williams RM (2008) Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228). Org Lett 10:613-616
74. Groll M, Huber R, Potts BCM (2006) Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128:5136-5141
75. Gryder BE, Sodji QH, Oyelere AK (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:505-524
76. Hackmann C (1952) Experimentelle untersuchungen uber die wirkung von actinomycin C. Z Krebsforsch 58:607-613
77. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J Org Chem 61:6594-6600
78. Hamann MT, Scheuer PJ (1993) Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 115:5825-5826
79. Hamann PR, Upeslacis J, Borders DB (2005) Enediynes. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products. Taylor and Francis, Boca Raton, pp 451-474
80. Hamann PR, Upeslacis J, Borders DB (2012) Enediynes. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 575-621
81. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T (1992) Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 45:1746-1752
82. Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM (2012) A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax™). Epigenomics 4:571-589
83. Hecht SM (1986) The chemistry of activated bleomycin. Acc Chem Res 19:383-391
84. Hecht SM (1994) RNA degradation by bleomycin, a naturally occurring bioconjugate. Bioconjugate Chem 5:513-526
85. Hecht SM (2005) Bleomycin group antitumor agents. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products. Taylor and Francis, Boca Raton, pp 357-381
86. Hecht SM (2012) Bleomycin group antitumor agents. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 451-478
87. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909
88. Herbertson RA, Tebbutt NC, Lee F-T, MacFarlane DJ, Chappell B, Micallef N, Lee S-T, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM (2009) Phase I biodistribution and pharmacokinetic study of Lewis Y targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 15:6709-6715
89. Hill RT, Hamann MT, Enticknap J, Rao KV (2005) Kahalalide-producing bacteria and methods of identifying kahalalide-producing bacteria and preparing kahalalides. WO 2005042720 A2, 12 May 2005
90. Hirata Y, Uemura D (1986) Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem 58:701-710
91. Ho R, Nievergelt A, Pires CS, Cuendet M (2012) Histonedeacetylases as cancer chemoprevention targets for natural products. In: ur-Rahman A (ed) Studies in Natural Products Chemistry, vol 38. Elsevier, Amsterdam, pp 247-267
92. Hoefle G, Reichenbach H (2005) Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products. Taylor and Francis, Boca Raton, pp 413-450
93. Hoefle G, Reichenbach H (2012) Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 513-573
94. Holt TG (1986) The isolation and structural characterization of the ecteinascidins. PhD Thesis, University of Illinois at Urbana-Champaign
95. Horsman GP, Chen Y, Thorson JS, Shen B (2010) Polyketide synthase chemistry does not direct biosynthetic divergence between 9- and 10-membered enediynes. Proc Natl Acad Sci USA 107:11331-11335
96. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang X-F, Yao T-P (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458
97. Ichikawa N, Sasagawa M, Yamamoto M, Komaki H, Yoshida Y, Yamazaki S, Fujita N (2013) DoBISCUIT: a database of secondary metabolite biosynthetic gene clusters. Nucleic Acids Res 41:D408-D414
98. Igarashi Y, Yanase S, Sugimoto K, Enomoto M, Miyanaga S, Trujillo ME, Saiki I, Kuwahara S (2011) Lupinacidin C, an inhibitor of tumor cell invasion from Micromonospora lupini. J Nat Prod 74:862-865
99. Ikeda Y, Idemoto H, Hirayama F, Yamamoto K, Iwao K, Asao T, Munakata T (1983) Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation. J Antibiot 36:1279-1283
100. Ito A, Kawaguchi Y, Lai C-H, Kovacs JJ, Higashimoto Y, Appella E, Yao T-P (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21:6236-6245
101. Izzo I, Acosta GA, Tulla-Puche J, Cupido T, Martin-Lopez MJ, Cuevas C, Albericio F (2010) Solid-phase synthesis of aza-kahalalide F analogues: (2R,3R)-2-amino-3-azidobutanoic acid as precursor of the aza-threonine. Eur J Org Chem 2010:2536-2543
102. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FAE, Giaccone G (2005) Kahalalide F induces necrosis-like cell death that Involves depletion of erbB3 and inhibition of Akt signaling. Mol Pharmacol 68:502-510
103. Jiménez JC, López-Maciá A, Gracia C, Varón S, Carrascal M, Caba JM, Royo M, Francesch AM, Cuevas C, Giralt E, Albericio F (2008) Structure-activity relationship of kahalalide F synthetic analogues. J Med Chem 51:4920-4931
104. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
105. Kageyama M, Tamura T, Nantz MH, Roberts JC, Somfai P, Whritenour DC, Masamune S (1990) Synthesis of bryostatin 7. J Am Chem Soc 112:7407-7408
106. Keck GE, Kraft MB, Truong AP, Li W, Sanchez CC, Kedei N, Lewin NE, Blumberg PM (2008) Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: bryostatin look-alikes that mimic phorbol ester function. J Am Chem Soc 130:6660-6661
107. Keck GE, Poudel YB, Cummins TJ, Rudra A, Covel JA (2010) Total synthesis of bryostatin 1. J Am Chem Soc 133:744-747
108. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Investig New Drugs 23:489-493
109. Kingston DGI, Newman DJ (2005) The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries. Curr Opin Drug Discov Dev 8:207-227
110. Kishi Y, Fang FG, Forsyth CJ, Scola PM, Yoon SK (1995) Halichondrins and related compounds, US 5436238 A, 25JUL1995
111. Koehn FE (2006) Therapeutic potential of natural product signal transduction agents. Curr Opin Biotechnol 17:631-637
112. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol™). J Biol Chem 272:2534-2541
113. Kraft AS, Smith JB, Berkow RL (1986) Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 83:1334-1338
114. Kristelett R, Stimson L, Workman P, Aherne W (2004) Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 9:135-154
115. Krohn K (2008) Anthracycline chemistry and biology I. Topics in current chemistry, vol 282. Springer, Heidelberg
116. Krohn K (2008) Anthracycline chemistry and biology II. Topics in current chemistry, vol 283. Springer, Heidelberg
117. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth P (2000) Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) study. Am J Clin Oncol 23:273-277
118. Kusari S, Hertweck C, Spiteller M (2012) Chemical ecology of endophytic fungi: origins of secondary metabolites. Chem Biol 19:792-798
119. Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277-1286
120. Lee J, Currano JN, Carroll PJ, Joullie MM (2012) Didemnins, tamandarins and related natural products. Nat Prod Rep 29:404-424
121. Lee J, Grenier L, Holson E, Slocum K, Coco J, Ge J, Normant E, Hoyt J, Lim AR, Cushing J (2008) IPI-493, a potent, oral bioavailable Hsp90 inhibitor of the ansamycin class. Eur J Cancer Suppl 6:Abst 153
122. Li KW, Wu J, Xing W, Simon JA (1996) Total synthesis of the antitumor depsipeptide FR-901,228. J Am Chem Soc 118:7237-7238
123. Li L, Deng W, Song J, Ding W, Zhao Q-F, Peng C, Song W-W, Tang G-L, Liu WC (2008) Characterization of the saframycin A gene cluster from Streptomyces lavendulae NRRL 11002 revealing a nonribosomal peptide synthetase system for assembling the unusual tetrapeptidyl skeleton in an iterative manner. J Bact 190:251-263
124. Li Z (2009) Advances in marine microbial symbionts in the China Sea and related pharmaceutical metabolites. Mar Drugs 7:113-129
125. Longo-Sorbello GSA, Gao H, Mishra PJ, Kamen B, Soto A, Jimeno J, Aracil M, De Paz MFP, Bertino JR, Banerjee D (2009) Heparin and suramin alter plitidepsin uptake via inhibition of GPCR coupled signaling. J Chemother 21:550-557
126. Lopanik NB, Lindquist N, Targett N (2004) Potent cytotoxins produced by a microbial symbiont protect host larvae from predation. Oecologia 139:131-139
127. Lopanik NB, Shields JA, Buchholz TJ, Rath CM, Hothersall J, Haygood MG, Hakansson K, Thomas CM, Sherman DH (2008) In vivo and in vitro trans-acylation by bryP, the putative bryostatin pathway acyltransferase derived from an uncultured marine symbiont. Chem Biol 15:1175-1186
128. Lopez-Macia A, Jimenez JC, Royo M, Giralt E, Alberico F (2001) Synthesis and structure determination of kahalalide F. J Am Chem Soc 123:11398-11401
129. Lu C, Shen Y (2007) A novel ansamycin, naphthomycin K from Streptomyces sp. J Antibiot 60:649-653
130. Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64:907-910
131. Lundberg DS, Lebeis SL, Paredes SH, Yourstone S, Gehring J, Malfatti S, Tremblay J, Engelbrektson A, Kunin V, del Rio TG, Edgar RC, Eickhorst T, Ley RE, Hugenholtz P, Tringe SG, Dangl JL (2012) Defining the core Arabidopsis thaliana root microbiome. Nature 488:86-90
132. Manaviazar S, Frigerio M, Bhatia GS, Hummersone MG, Aliev AE, Hale KJ (2006) Enantioselective formal total synthesis of the antitumor macrolide bryostatin 7. Org Lett 8:4477-4480
133. Marques JV, Kim K-W, Lee C, Costa MA, May GD, Crow JA, Davin LB, Lewis NG (2013) Next generation sequencing in predicting gene function in podophyllotoxin biosynthesis. J Biol Chem 288:466-479
134. Mauger AB, Lackner H (2005) The actinomycins. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products. Taylor and Francis, Boca Raton, pp 281-297
135. Mauger AB, Stuart OA, Katz E (1991) Synthesis and properties of some peptide analogs of actinomycin D. J Med Chem 34:1297-1301
136. McAlpine JB, Swanson SJ, Jackson M, Whittern DN (1991) Revised NMR assignments for rapamycin. J Antibiot 44:688-690
137. McCormack PL (2012) Carfilzomib. Drugs 72:2023-2032
138. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403-10408
139. Menzella HG, Carney JR, Li Y, Santi DV (2010) Using chemobiosynthesis and synthetic mini-polyketide synthases to produce pharmaceutical intermediates in Escherichia coli. Appl Environ Microbiol 76:5221-5227
140. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404:1-13
141. Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker AM, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom STC, McConkey DJ, Palladino MA, Spear MA (2012) Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investig New Drugs 30:2303-2317
142. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540-545
143. Morgan RJ Jr, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz H-J, Doroshow JH (2012) Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Investig New Drugs 30:723-728
144. Moss C, Green DH, Perez B, Velasco A, Henriquez R, McKenzie JD (2003) Intracellular bacteria associated with the ascidian Ecteinascidia turbinata: phylogenic and in situ hybridization analysis. Mar Biol 143:99-110
145. Murphy BT, Jensen PR, Fenical W (2012) The chemistry of marine bacteria. In: Fattorusso E, Gerwick WH, Taglialatela-Scafati O (eds) Handbook of marine natural products. Springer, New York, pp 153-190
146. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241:126-133
147. Nakano H, Omura S (2009) Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. J Antibiot 62:17-26
148. Newman DJ (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51:2589-2599
149. Newman DJ (2012) The bryostatins. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 199-218
150. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477
151. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311-335
152. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022-1037
153. Nguyen H, Ma G, Gladysheva T, Fremgen T, Romo D (2010) Bioinspired total synthesis and human proteasome inhibitory activity of (-)-salinosporamide A, (-)-homosalinosporamide A, and derivatives obtained via organonucleophile promoted bis-cyclizations. J Org Chem 76:2-12
154. Nock CJ, Brell JM, Bokar JA, Cooney MM, Cooper B, Gibbons J, Krishnamurthi S, Manda S, Savvides P, Remick SC, Ivy P, Dowlati A (2011) A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investig New Drugs 29:126-130
155. Nützmann H-W, Reyes-Dominguez Y, Scherlach K, Schroeckh V, Horn F, Gacek A, Schümann J, Hertweck C, Strauss J, Brakhage AA (2011) Bacteria-induced natural product formation in the fungus Aspergillus nidulans requires Saga/Ada-mediated histone acetylation. Proc Natl Acad Sci USA 108:14282-14287
156. Ochi K, Hosaka T (2013) New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters. Appl Microbiol Biotechnol 97:87-98
157. Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S (2000) Total synthesis of bryostatin 3. Angew Chem Int Ed 39:2290-2294
158. Ohnishi Y, Ishikawa J, Hara H, Suzuki H, Ikenoya M, Ikeda H, Yamashita A, Hattori M, Horinouchi S (2008) Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350. J Bact 190:4050-4060
159. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R (1977) A new alkaloid AM-2282 of Streptomyces origin. Fermentation, isolation and preliminary characterization. J Antibiot 30:275-282
160. Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51:1505-1529
161. Park SR, Han AR, Ban Y-H, Yoo YJ, Kim EJ, Yoon YJ (2010) Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol 85:1227-1239
162. Patel RM (2011) Trabectedin: a novel molecular therapeutic in cancer. Int J Curr Pharm Res 3:65-70
163. Pei X-Y, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839-3852
164. Perez-Matos AE, Rosado W, Govind NS (2007) Bacterial diversity associated with the Caribbean tunicate Ecteinascidia turbinata. Anton van Leeuwen 92:155-164
165. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR (2005) Phase II trial of dolastatin-10 in patients with advanced breast cancer. Investig New Drugs 23:257-261
166. Piggott AM, Karuso P (2008) Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. ChemBioChem 9:524-530
167. Potharla VY, Wesener SR, Cheng Y-Q (2011) New insights into the genetic organization of the FK228 biosynthetic gene cluster in Chromobacterium violaceum No. 968. Appl Environ Microbiol 77:1508-1511
168. Rath CM, Janto B, Earl J, Ahmed A, Hu FZ, Hiller L, Dahlgren M, Kreft R, Yu F, Wolff JJ, Kweon HK, Christiansen MA, Hykansson K, Williams RM, Ehrlich GD, Sherman DH (2011) Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product et-743. ACS Chem Biol 6:1244-1256
169. Reichenbach H, Hoefle G (2008) Discovery and development of the epothilones: a novel class of antineoplastic drugs. Drugs R&D 9:1-10
170. Remiszewski SW (2002) Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr Opin Drug Discov Dev 5:487-499
171. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17:6417-6427
172. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007
173. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93:5705-5708
174. Rinehart Jr KL, Lithgow-Bertelloni AM (1991) Deshydrodidemnine b, WO 1991004985 A1, 18APR1991
175. Rinehart K, Holt TG, Fregeau NL, Stroh JG, Kiefer PA, Sun F, Li LH, Martin DG (1990) Ecteinascidins 729, 743, 745, 759A, 759B and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 55:4512-4515
176. Rinehart KL, Gloer JB, Hughes RG, Renis HE, McGovren JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH (1981) Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933-935
177. Rodríguez I, Polanco C, Cuevas F, Mendez P, Cuevas C, Gallego P, Munt S, Manzanares I (2002) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them. WO 0202596 A, 10JAN2002
178. Rossi C, Fincham CI, D'Andrea P, Porcelloni M, Ettorre A, Mauro S, Bigioni M, Binaschi M, Maggi CA, Nardelli F, Parlani M, Fattori D (2011) 4-N-hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors. Bioorg Med Chem Lett 21:6767-6769
179. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F, von Schack D, McDonald L, Zaleska MM, Wood A, Reinhart PH, Magolda RL, Skotnicki J, Pangalos MN, Koehn FE, Carter GT, Abou-Gharbia M, Graziani EI (2008) Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA 105:33-38
180. Salas JA, Méndez C (2009) Indolocarbazole antitumour compounds by combinatorial biosynthesis. Curr.ent Opin. Chem Biol 13:152-160
181. Sanchez JF, Somoza AD, Keller NP, Wang CCC (2012) Advances in Aspergillus secondary metabolite research in the post-genomic era. Nat Prod Rep 29:351-371
182. Satoh N, Yokoshima S, Fukuyama T (2011) Total synthesis of (-)-salinosporamide A. Org Lett 13:3028-3031
183. Schulte G (1952) Erfahrungen mit neuen zytostatischen mitteln bei hamoblastosen und carcinomen und die abgrenzung ihrer wirkungen gegen roentgentherapie. Z Krebsforsch 58:500-503
184. Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A (2012) Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer. J Thorac Oncol 7:751-754
185. Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot 28:727-732
186. Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM (2005) The mechanism of action of kahalalide F: variable cell permeability in human hepatoma cell lines. Eur J Cancer 41:1637-1644
187. Shendure J, Ji H (2008) Next-generation DNA sequencing. Nat Biotechnol 26:1135-1145
188. Sigel MM, Wellham LL, Lichter W, Dudeck LE, Gargus JL, Lucas LH (1970) Food-drugs from the sea: proceedings 1969. Marine Technology Society, Washington, D.C.
189. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BHB, Crews CM (1999) Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9:2283-2288
190. Snader KM (2005) Benzoquinone ansamycins. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 1st edn. Taylor and Francis, Boca Raton, pp 339-356
191. Snader KM (2012) Benzoquinone ansamycins. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. Taylor and Francis, Boca Raton, pp 429-450
192. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250
193. Stolfa DA, Stefanachi A, Gajer JM, Nebbioso A, Altucci L, Cellamare S, Jung M, Carotti A (2012) Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. Chem Med Chem 7:1256-1266
194. Strobel G, Daisy B (2003) Bioprospecting for microbial endophytes and their natural products. Microbiol Mol Biol Rev 67:491-502
195. Strobel G, Daisy B, Castillo U, Harper J (2004) Natural products from endophytic microorganisms. J Nat Prod 67:257-268
196. Stubbe J-A, Kozarich JW (1987) Mechanisms of bleomycin-induced DNA degradation. Chem Rev 87:1107-1136
197. Suárez Y, González L, Cuadrado A, Berciano M, Lafarga M, Muñoz A (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2:863-872
198. Sun M-K, Hongpaisan J, Alkon DL (2009) Postischemic PKC activation rescues retrograde and anterograde long-term memory. Proc Natl Acad Sci USA 106:14676-14680
199. Sun M-K, Hongpaisan J, Nelson TJ, Alkon DL (2008) Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci USA 105:13620-13625
200. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103:17408-17413
201. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F (1986) Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochim Biophys Res Comm 135:397-402
202. Tan ML, Choong PFM, Dass CR (2009) Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 61:131-142
203. Tanaka Y, Hosaka T, Ochi K (2010) Rare earth elements activate the secondary metabolite-biosynthetic gene clusters in Streptomyces coelicolor A3(2). J Antibiot 63:477-481
204. Tang L, Chung L, Carney JR, Starks CM, Licari P, Katz L (2005) Generation of new epothilones by genetic engineering of a polyketide synthase in Myxococcus xanthus. J Antibiot 58:178-184
205. Tao Z-F, Konishi K, Keith G, Hecht SM (2006) An efficient mammalian transfer RNA target for bleomycin. J Am Chem Soc 128:14806-14807
206. Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A (2010) New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Bioorg Med Chem 18:4187-4194
207. Tiwari R, Kalra A, Darokar MP, Chandra M, Aggarwal N, Singh AK, Khanuja SPS (2010) Endophytic bacteria from Ocimum sanctum and their yield enhancing capabilities. Curr Microbiol 60:167-171
208. Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG (2010) Bryostatins: biological context and biotechnological prospects. Curr Opin Biotechnol 21:834-842
209. Trost BM, Dong G (2010) Total synthesis of bryostatin 16 using a Pd-catalyzed diyne coupling as macrocyclization method and synthesis of C20-epi-bryostatin 7 as a potent anticancer agent. J Am Chem Soc 132:16403-16416
210. Trost BM, Frontier AJ, Thiel OR, Yang H, Dong G (2011) Total synthesis of bryostatins: the development of methodology for the atom-economic and stereoselective synthesis of the ring C subunit. Chem Eur J 17:9762-9776
211. Tsueng G, Lam KS (2007) Stabilization effect of resin on the production of potent proteasome inhibitor NPI-0052 during submerged fermentation of Salinispora tropica. J Antibiot 60:469-472
212. Tsuji N, Kobayashi N, Nagashima K, Wakisaka Y, Koizumi K (1976) A new antifungal antibiotic, trichostatin. J Antibiot 29:1-6
213. Tsukimoto M, Nagaoka M, Shishido Y, Fujimoto J, Nishisaka F, Matsumoto S, Harunari E, Imada C, Matsuzaki T (2011) Bacterial production of the tunicate-derived antitumor cyclic depsipeptide didemnin B. J Nat Prod 74:2329-2331
214. Udwary DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, Moore BS (2007) Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci USA 104:10376-10381
215. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47:301-310
216. Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60 src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6:2198-2206
217. Uehara Y, Murakami Y, Mizuno S, Kawalt S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164(1):294-298
218. Van Lanen SG, Shen B (2008) Biosynthesis of enediyne antitumor antibiotics. Curr Topics Med Chem 8:448-459
219. Velasco A, Acebo P, Gomez A, Schleissner C, Rodriguez P, Aparicio T, Conde S, Munoz R, de la Calle F, Garcia JL, Sanchez-Puelles JM (2005) Molecular characterization of the safracin biosynthetic pathway from Pseudomonas fluorescens A2-2: designing new cytoxic compounds. Mol Microbiol 56:144-154
220. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28:721-726
221. 2+-binding functional group. ACS Med Chem Lett 3:505-508
222. Vlahov IR, Vite GD, Kleindl PJ, Wang Y, Santhapuram HK, You F, Howard SJ, Kim SH, Lee FF, Leamon CP (2010) Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg Med Chem Lett 20:4578-4581
223. von Döhren H (2009) A survey of nonribosomal peptide synthetase (NRPS) genes in Aspergillus nidulans. Fungal Genet Biol 46:S45-S52
224. von Mehren M, Balcerak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A (2004) Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma 8:107-111
225. von Mering C, Hugenholtz P, Raes J, Tringe SG, Doerks T, Jensen LJ, Ward N, Bork P (2007) Quantitative phylogenetic assessment of microbial communities in diverse environments. Science 315:1126-1130
226. Waksman SA, Woodruff HB (1940) Bacteriostatic and bactericidal substances produced by a soil Actinomyces. Proc Soc Exp Biol Med 45:609-614
227. Wang D, Darwish DS, Schreurs BG, Alkon DL (2008) Analysis of long-term cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response. Behav Pharmacol 19:245-256
228. Wang S-Y, Lee Y-L, Lai Y-H, Chen JJW, Wu W-L, Yuann J-MP, Su W-L, Chuang S-M, Hou M-H (2012) Spermine attenuates the action of the DNA intercalator, actinomycin D, on DNA binding and the inhibition of transcription and DNA replication. PLoS ONE 7:e47101
229. Wen S, Packham G, Ganesan A (2008) Macrolactamization versus macrolactonization: total synthesis of FK228, the depsipeptide histone deacetylase inhibitor. J Org Chem 73:9353-9361
230. Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, Verma VA (2011) Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci USA 108:6721-6726
231. Wender PA, Reuber J (2011) Function oriented synthesis: preparation and initial biological evaluation of new A-ring-modified bryologs. Tetrahedron 67:9998-10005
232. White JD, Sundermann KF, Wartmann M (2002) Synthesis, conformational analysis, and bioassay of 9,10-didehydroepothilone D. Org Lett 4:995-997
233. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328
234. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174
235. Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, Koehn FE, McConnell OJ (1990) Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J Org Chem 55:4508-4512
236. Wu D, Hugenholtz P, Mavromatis K, Pukall R, Dalin E, Ivanova NN, Kunin V, Goodwin L, Wu M, Tindall BJ, Hooper SD, Pati A, Lykidis A, Spring S, Anderson IJ, D'haeseleer P, Zemla A, Singer M, Lapidus A, Nolan M, Copeland A, Han C, Chen F, Cheng J-F, Lucas S, Kerfeld C, Lang E, Gronow S, Chain P, Bruce D, Rubin EM, Kyrpides NC, Klenk H-P, Eisen JA (2009) A phylogeny-driven genomic encyclopaedia of Bacteria and Archaea. Nature 462:1056-1060
237. Xu Y, Kersten RD, Nam S-J, Lu L, Al-Suwailem AM, Zheng H, Fenical W, Dorrestein PC, Moore BS, Qian P-Y (2012) Bacterial biosynthesis and maturation of the didemnin anti-cancer agents. J Am Chem Soc 134:8625-8632
238. Yao Y-L, Yang W-M, Seto E (2001) Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 21:5979-5991
239. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target of cancer chemotherapy. Cancer Chemother Pharmacol 48:S20-S26
240. Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 17:423-430
241. Yoshida M, Matsuyama A, Komatsu Y, Nishino N (2003) From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351-2358
242. Younes A, Yasothan U, Kirkpatrick P (2012) Brentuximab vedotin. Nat Rev Drug Discov 11:19-20
243. Zech SG, Car M, Mohemmad QK, Narasimhan NI, Murray C, Rozamus LW, Dalgarno DC (2011) Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients. J Antibiot 64:649-654
244. Zheng L, Li G, Wang X, Pan W, Li L, Hua L, Liu F, Dang L, Mo M, Zhang K (2008) Nematicidal endophytic bacteria obtained from plants. Ann Microbiol 58:569-572